New diabetes drug shows promise in mid-stage trial
NCT ID NCT06393348
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 22 times
Summary
This study tested a new medication, HRS-7535, in 155 adults with type 2 diabetes whose blood sugar was not well controlled despite taking metformin and an SGLT2i. Participants received either the new drug or a placebo for 16 weeks. The main goal was to see if HRS-7535 lowers blood sugar levels (HbA1c) more than placebo, and also to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Guangdong, Guangzhou, 51020, China
Conditions
Explore the condition pages connected to this study.